Share Name Share Symbol Market Type Share ISIN Share Description
Eco Animal Health Group Plc LSE:EAH London Ordinary Share GB0032036807 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 385.00p 370.00p 400.00p 385.00p 385.00p 385.00p 130 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 74.6 15.2 17.6 21.9 260

Eco Animal Health Share Discussion Threads

Showing 126 to 150 of 1050 messages
Chat Pages: Latest  6  5  4  3  2  1
DateSubjectAuthorDiscuss
17/3/2010
20:25
Agree. They wouldn't embark on such a joint venture if they weren't confident the FDA approval was in the bag. It appears this deal gives them access to low cost manufacturing in China and the fact this facility is already FDA approved is one less hurdle.
audigger
17/3/2010
19:21
imho i think today's agreement implied something about that... smell
smelleroo
17/3/2010
07:28
All we need now is the FDA approval and away we go!
audigger
15/3/2010
21:11
up all of 1/2p today, but the recovery continues smell
smelleroo
12/3/2010
19:51
it seems to me that there was an overhang i.e. someone wanted to sell their stake and the eco share price had to be worked to a level to attract a buyer(s). 136p looks like the price at which this overhang cleared, this is going back up! would explain share price movement of late- going down on tiny volume. smell
smelleroo
12/3/2010
16:59
Looking like buys
audigger
12/3/2010
15:25
Interesting trades today.....buys or sells?
audigger
10/3/2010
20:13
http://www.proactiveinvestors.co.uk/companies/news/14233/eco-animal-health-group-moves-into-us-and-china-could-be-transformational-14233.html
ariane
10/3/2010
20:04
ariane, i see this is from proactive investors. who is the author Michael Sweeney? smell
smelleroo
10/3/2010
08:59
Eco Animal Health Group: moves into US and China could be transformational by Michael Sweeney ECO Animal Health Group (AIM: EAH) is a specialized veterinary drug company and a leader in the development, registration, and marketing of pharmaceutical products for global animal health markets. With a careful and responsible application of science, ECO delivers products to promote animal well-being and sustainable productivity. ECO's proprietary patented drug is Aivlosin®, which is a macrolide antibiotic for the treatment of respiratory and enteric diseases in pigs and poultry. Aivlosin targets a wide range of diseases that span from enzootic pneumonia to swine dysentery. The drug has been approved for use in pigs and poultry in Europe, South Africa, Japan, Asia, and South America. ECO expects to receive approvals this year for use in pigs in the United States. The Company now holds over 600 marketing authorizations in over 50 countries, and has developed strong relationships with distribution partners globally. With 100 employees located in five offices around the world and £19.3 million in revenues for FY 2009, the Company's products are recognized as offering security to both distributors and end users. Investment Thesis Aivlosin® now accounts for more than half of global sales for ECO. Sales in China during FY 2009 were more than 60% ahead of the previous year, and expectations for FY 2010 indicate similar progress. China is the largest market opportunity for ECO products in which it has a joint venture for sales and marketing ("ECO-BIOK"), and ECO is currently examining other joint in China. The Company is working on launch and distribution plans for the U.S. market, expecting to receive first marketing authorizations for Aivlosin from the Food and Drug Administration (FDA) in 2010. ECO is forecast by Cenkos Securities to increase its revenues to £22.4m in the FY March 31, 2010 and to £28.5m in 2011. EBITDA plus share-based payments and exceptional items are estimated at £3.6m and £5.3m respectively, which should translate to earnings per share of 4.7 pence and 7.4 pence. Cenkos expects ECO to produce step increases in earnings as new marketing authorizations are granted and new products are launched. Additionally it expects ECO's capital expenditure to fall substantially as the product registration program nears completion, resulting in increased cash flow. ECO's first half revenue from 4/1/09 to 9/30/09 rose 11% year to £8.9 million, while EBITDA jumped 32% to £1.94 million. The group had net cash of £3.2 at the end of the period. The increase in revenues was largely due to stronger sales of Aivlosin, which rose 10% after further marketing authorizations were secured in Europe. ECO has offered an upbeat outlook for the rest of FY 2010 (FYE is 3/31/10), as they expect business performance to improve further and projecting that Ecomectrin sales would pick up in the second half of the year. In 2009, EBITDA plus share-based payments and exceptional items increased 66.9% to £3.74 million (2008: £2.24 million). ECO paid a total dividend of 7.15 pence per share in 2008 and 2009, and it generated £3 million in cash from operating activities during 2009. ECO's Core Products Aivlosin® is ECO's proprietary patented macrolide drug, and it contains the innovative antibiotic Tylvalosin, The inclusion of Tylvalosin allows the drug to rapidly be absorbed and concentrated in target tissues to provide proven control of major respiratory and enteric diseases in both pigs and poultry. It is highly effective against a range of economically substantial diseases in pigs and poultry including: • Enzootic Pneumonia • Ileitis/PPE • Swine Dysentery • Mycoplasmosis • ORT • Necrotic Enteritis ECO continues to explore other potential uses of Aivlosin in production animals beyond pigs and poultry, such as cattle and horses. In June 2008, ECO was granted a marketing authorization from the European Commission for Aivlosin® granules for oral solution for poultry. It is the rapid absorption of Aivlosin® which results in a swift resolution of the disease and a fast return to productive health that makes it profitable for farmers to use when compared with older generation treatments. This authorization allows Aivlosin® to be marketed in Europe for the treatment and prevention of mycoplasmal respiratory disease in poultry, a segment estimated to be worth over £10 million per annum at the manufacturer level. In March 2009, ECO announced that it had received a positive opinion from the Committee for Medicinal Products for Veterinary Use of the European Medicines Agency for the use of Aivlosin® granules for oral solution for medicated drinking water for pigs. The Aivlosin® granules dissolve readily in drinking water thus enabling the rapid, accurate and simultaneous treatment of large numbers of pigs that are more likely to drink than to eat. This will allow Aivlosin® to be marketed throughout Europe for the treatment and prevention of ileitis. It is estimated that this market segment is worth £18 million per annum at manufacturer level. Generic Drugs - ECO is also making progress in its development of a new range of generic medications for pets, adding to its existing Ecoheart dog heartworm tablet and Ecomectin horse paste products. ECO has a number of generic drugs including Ecotraz and Ecomintic (endectocides & other antiparasitics) for the treatment and prevention of parasites in cattle, sheep, pigs, horses, and dogs. For the treatment of bacterial infections in pigs, poultry & cattle, ECO owns and distributes Chlortet and Oxytet. ECO has been granted a marketing authorization in Mexico for Ecoheart Chewable Tablets for dogs. Ecoheart tablets prevent heartworm disease and are also effective in the treatment and control of roundworms and hookworms in dogs. Canine heartworm infection is transmitted by mosquitoes. It is potentially fatal and requires a monthly preventative treatment. Ecoheart Chewable Tablets is the first companion animal product for which ECO has received a marketing authorization in Latin America where the pet sector is an important and growing market. Further marketing authorizations in the key markets of the region are expected. Research - ECO plans to build on the collaborative research deal it signed in 2006 with the University of Cambridge to investigate new potential indications for Aivlosin. Studies already completed have indicated that Aivlosin appears to prevent the replication of certain common viruses, including influenza, in laboratory test systems, without damaging cell cultures. Researchers at the Virology Division of the university's Department of Pathology have been awarded a £500,000 grant by the UK Medical Research Council to extend their work investigating inhibition of influenza viruses, and ECO's management believes that this work could have far reaching and exciting commercial applications for the firm. Prospects for the Future In a very difficult economy, ECO has performed very well. Now with markets in China opening and the U.S. expected this year, ECO has the potential to make even more progress. This should be a real launching pad for the Company. While there is a risk for ECO in the amount of revenues coming from one product, it does appear to have a loyal and growing following around the world.
ariane
09/3/2010
22:03
illiquid stock, fallen or very small volume fundamentals firmly intact smell
smelleroo
09/3/2010
21:35
I am looking to buy in. The share drop has been a surprise and a little hard to explain apart from a lack of media/pi interest.
maxchampagne
09/3/2010
20:54
Very quiet on here as folks sit back and watch the share price decline by circa 36%. Has left me nursing a significant paper loss. However, assuming the fundamentals haven't changed, I remain optimistic about the outlook. Having said that, I'm very close to my stop-loss. It was the 30K trade that prompted me to post. Are the big boys about to buy-in ahead of news on the FDA approval? Was the share price walked down to help this? I'm very tempted to add at this price, but I first need to be reassured that there isn't any bad news behind the big fall in share price I would have expected the company to comment if there were, which again makes me think that this may be about to fly on the back of good news. The joys of AIM shares!
audigger
03/2/2010
14:19
Old news but never the less Friday, November 27, 2009 Cenkos says ECO Animal Health made solid progress in H1, maintains 'buy' stance "...According to Cenkos, ECO is also making progress in its development of a new range of generic medications for pets, adding to its existing Ecoheart dog heartworm tablet and Ecomectin horse paste products. The broker expects these developments to start contributing to revenues in 2011. Cenkos expects ECO to produce step increases in earnings as new marketing authorisations are granted and new products are launched. Additionally it expects ECO's capital expenditure to fall substantially as the product registration programme nears completion, resulting in a highly cash generative business." http://www.proactiveinvestors.co.uk/companies/news/12527/cenkos-says-eco-animal-health-made-solid-progress-in-h1-maintains-buy-stance--12527.html
aim_trader
03/2/2010
06:46
Well I was wrong about the slow climb back to 200! Encouraging to see ECO extending in to LATAM. Would like to hear the company's current view on projected sales in light of several recent product approvals. Would also be good to have some insight in the the FDA timeline as they must know roughly when their data package will be evaluated.
audigger
21/1/2010
07:42
Marked-up before opening today. Looks like things are warming-up as we climb slowly back to 200 plus.
audigger
15/1/2010
08:51
not another one smell
smelleroo
15/1/2010
08:47
Regulatory Approval TIDMEAH ECO Animal Health Group plc 15 January 2010 ECO RECEIVES REGISTRATION APPROVAL FOR TWO NEW AIVLOSIN® PRODUCTS On 26 and 29 October 2009 ECO Animal Health Group plc announced that its subsidiary ECO Animal Health Limited (ECO) had received positive opinions from the European Medicines Agency (EMEA) for two new products: · A concentrated form of Aivlosin® oral powder for pigs · Aivlosin® granules for oral solution for medicated drinking water for pheasants ECO is now pleased to report that the European Commission has granted registration approval for both these products and this allows the company to commence active marketing of them throughout Europe. The European Commission's approval marks yet another important step in ECO's continuing development of Aivlosin as a global veterinary product. It will further extend the marketing reach of Aivlosin®, ECO's patented macrolide antibiotic, which is used for the treatment of respiratory and enteric diseases in pigs and poultry. Contacts: ECO Animal Health Group plc Marc Loomes 020 8447 8899 Spiro Financial Anthony Spiro 020 8336 6196 Cenkos Securities plc Stephen Keys 020 7397 8926 (Nominated Adviser) ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for animals. Our products for these global growth markets promote well-being. Our financial goals are achieved through the careful and responsible application of science to generate value for our shareholders
waldron
05/1/2010
11:47
Agree. Its a sensible use of equity. Would be nice to get FDA approval in 1Q and then to start to realise significqant income/profit from all these product approvals.
audigger
05/1/2010
10:26
Todays announcement of the purchase of the remaining 80 percent of Ecopharma in Japan is immediately earnings enhancing and is an excellent start to what is hopefully going to be a transformational year for Eco Animal Health.
ltinvestor
21/12/2009
21:52
It's smart to fund growth with equity in these markets. Lawrence look well placed to benefit in the year's ahead. They've had to drop the price to get it away, but not too much dilution for a sizeable slug of cash that will be put to good use.
topvest
21/12/2009
20:12
surprised the shares were so weak today, guess the mm's were left to the own devices to evaluate this. this is very good news, the proceeds are NOT being used to pay down debt etc. it does seem that 2010 will be very exciting for eah! this silly price movement is a topping up opportunity, assuming you can buy stock! smell
smelleroo
21/12/2009
08:42
Well looks like the excitement has come early! Nothing like a bit of dilution to present a perfect buying opportunity. I very nearly bought 3Ks worth last Wednesday but was suspicious as to whether there was a reason behind the series of small drops. Clearly there was. Of course the question now is will this drift a little further south or we we see a quick bonce. I suspect the latter (based on the fundamentals going forward), so I feel a pre-Christmas purchase coming on.
audigger
21/12/2009
07:20
china and usa references in today's news. merry christmas and here is to a great 2010 for eah! next year should be very exciting! smell
smelleroo
28/11/2009
08:13
Well I didn't notice that the half-year report came out yesterday. It all looks very positive. Interesting to see they have an MRC grant for the anti-viral work which at least shows it maintains some credibility as an option for Aivlosin. Its strange we had the big fall against the backdrop of this good update, hopefully we may see another jump depending on overall market sentiment which is lokking rather volatile. I still can't get my hands on cash to buy more until Jan, so I'm hoping it doesn't gain too much until then. FDA approaval should be the prompt for a significant increase in share price especially if they are already gearing-up to respond to this.
audigger
Chat Pages: Latest  6  5  4  3  2  1
Your Recent History
LSE
EAH
Eco Animal..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190822 08:58:46